Clinical Data ATS 2026: PABPC4 gene identified as a key driver of emphysema in COPD Pharmaceutical TechnologyPABPC4 genetic variants found to be associated with mitochondrial dysfunction driving emphysema in COPD.RespiratoryRead full story pharminent May 21, 2026 (Last updated: May 21, 2026) Pharmaceutical Technology PABPC4 genetic variants found to be associated with mitochondrial dysfunction driving emphysema in COPD. Respiratory Read full story Post navigation Previous: ATS 2026: Long-term data show durable benefit of Trikafta for cystic fibrosisNext: Bayer gets swift review for Kerendia in type 1 diabetes Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026